2023 EWC Sponsor: Lumea

Where tissue meets tech

Leveraging preanalytic tech to make digital pathology both viable and valuable

Combining science and innovation to measurably elevate patient care

We are passionate about safeguarding preanalytic tissue. That is why we developed revolutionary devices that save cost, increase tissue yield, reduce fragmentation, maintain anatomic orientation, and reduce preservation time while keeping genetic and proteomic quality.

A Digital Pathology Solution With High-Yield Results

To derive real value from digital pathology the journey has to start at the beginning — with the patient.

Lumea’s proprietary specimen-handling devices, combined with innovative software solutions, maximize efficiencies, and value throughout the entire workflow, from the surgery center to the diagnosis.

Revolutionizing Diagnostic Medicine

Recognizing a Problem with Digital Pathology
Matthew Leavitt, a Stanford-trained pathologist, foresaw that digital was the future of pathology and wanted to use it in his practice. He and his colleague Jared Szymanski purchased a whole slide image scanner and some digital solutions, only to discover that they added more problems than they solved in cost and complexity. With the dream of making viable digital pathology a reality, Matt left his day job and founded the digital pathology company Lumea.

The Answer is the Tissue
Matt and the Lumea team realized that too many digital pathology solutions started at the scanner. They believed the answer lay within the tissue – starting at the point of specimen acquisition. They focused on inventing products for physicians and labs that would increase efficiency, improve patient safety, and give an actual return on investments in digital pathology.

Lumea is the Solution
Lumea’s DaVincian team developed and commercialized the most advanced digital pathology platform on the market today. Their solutions standardized and connected clinic, laboratory, and pathology workflows. This digital pathology company has deployed proprietary tissue handling technologies, specimen tracking, laboratory efficiency improvements, a seamless digital signout process, and added invaluable AI and genetic testing partnerships to improve the quality of practices and allows businesses to scale.